Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE - PubMed
4 days ago
- #heart failure
- #clinical trial
- #empagliflozin
- Empagliflozin improved clinical outcomes in patients hospitalized for heart failure (HF) in the EMPULSE study.
- The study compared efficacy, safety, and tolerability of empagliflozin in de novo heart failure (NHF) vs acute decompensated heart failure (ADHF) subgroups.
- Participants with NHF were younger, had fewer comorbidities, higher blood pressure, and better symptom scores compared to ADHF.
- The win ratio for clinical benefits was similar between NHF (1.29) and ADHF (1.39), with no significant interaction.
- Diuretic response was greater with empagliflozin in NHF than in ADHF, with significant differences observed from day 15 onwards.
- Empagliflozin was well-tolerated, with lower frequencies of adverse events compared to placebo.
- The study supports in-hospital initiation of empagliflozin for all patients with acute HF, regardless of NHF or ADHF status.